New research evaluates clinical trials investigating post-acute COVID-19 syndrome treatment

In a recent article published in Clinical Microbiology and Infection, researchers reviewed all registered trials currently investigating potential treatment options for post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS).

Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds - The New York Times

COVID-19 therapeutics: Challenges and directions for the future

Post-acute COVID-19 syndrome

Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial - eClinicalMedicine

Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19

Long COVID and its Management

Long COVID and cardiovascular disease: a learning health system approach

The NIH poured $1 billion into long Covid research, with little to show for it

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study

Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns — United States, June 2020